Committee for Advanced Therapies (CAT)
Draft agenda for the meeting on 15 June 2023

Chair: Ilona Reischl
15 June 2023, 09:00 – 18:00

Health and safety information
In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
## Table of contents

### 1. Introduction 5
1.1. Welcome and declarations of interest of members, alternates and experts 5  
1.2. Adoption of agenda 5  
1.3. Adoption of the minutes 5

### 2. Evaluation of ATMPs 5
2.1. Opinions 5  
2.2. Oral explanations 5  
2.3. Day 180 list of outstanding issues 5  
2.4. Day 120 list of questions 5  
2.5. Day 80 assessment reports 5  
2.6. Update on ongoing initial applications 5  
2.7. New applications 6  
2.7.1. fidanacogene elaparvovec - PRIME - Orphan - EMEA/H/C/004774 6  
2.8. Withdrawal of initial marketing authorisation application 6  
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 6  
2.10. Companion diagnostics 6  
2.10.1. Initial consultation 6  
2.10.2. Follow-up consultation 6  
2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 6  
2.11.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0031 6  
2.11.2. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0032/G 7  
2.11.3. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0034 7  
2.11.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0013/G 7  
2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G 7  
2.11.6. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0019 7  
2.11.7. CARVYKTI - ciltaçabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0016 8  
2.11.8. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0062/G 8  
2.11.9. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0069 8  
2.11.10. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0070/G 8  
2.11.11. Libmeldy - atidarsage me autotemcel - Orphan - EMEA/H/C/005321/II/0015 9  
2.12. Extension applications 9  
2.13. Other Post-Authorisation Activities 9  
2.13.1. CARVYKTI - ciltaçabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/013 9
2.13.2. Hemgenix - etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/REC/005 .......... 9
2.13.3. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/002.1 ....... 9
2.13.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/004.1 ...... 10
2.13.5. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/MEA/005 ........ 10
2.13.6. Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/ANX/004.4 ................................................................. 10
2.13.7. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/REC/009 .............. 10
2.14. GMP and GCP inspections requests ................................................................. 11

3. Certification of ATMPs .................................................................................. 11
3.1. Opinion ......................................................................................................... 11
3.2. Day 60 Evaluation Reports ........................................................................ 11
3.3. New Applications ......................................................................................... 11

4. Scientific Recommendation on Classification of ATMPs ...................... 11
4.1. New requests – Appointment of CAT Coordinator ................................. 11
4.1.1. Neonatal human dermal fibroblast (nHDF) cell-produced living extracellular vascular tissue11
4.1.2. Bovine collagen membrane seeded with allogeneic mesenchymal stem cells derived from adipose tissue (ADSC) ......................................................... 11
4.1.3. Lymphocytic Choriomeningitis Virus (LCMV) reassortant strain exerting efficient anti-tumoral activity ................................................................. 12
4.1.4. Human Cardiomyocytes (CM), Human Stromal Cells (StC) ...................... 12
4.1.5. Doruxapapogenum ralaplasmidum (pGX3024), DNA plasmid encoding E6 and E7 proteins of HPV6 and HPV11 ............................................................... 12
4.1.6. TERT Ribonucleoprotein ......................................................................... 12
4.2. Day 30 ATMP scientific recommendation ................................................. 12
4.3. Day 60 revised scientific recommendation (following list of questions) ...... 12
4.4. Finalisation of procedure ............................................................................. 12
4.4.1. Living human adult allogeneic immunomodulatory progenitor (iMP) cells 12
4.4.2. Allogeneic viable natural killer (NK) cells CD56+ CD3- .............................. 13
4.4.3. Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene .......................... 13
4.5. Follow-up and guidance ............................................................................. 13

5. Scientific Advice ...................................................................................... 13
5.1. New requests - appointment of CAT Rapporteurs ...................................... 13
5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers 13
5.1.2. Scientific advice procedures starting at the next SAWP meeting .............. 13
5.2. Procedures discussed at SAWP – 1st reports, D40 JR’s, LoIs ..................... 14
5.3. Finalisation of D70 procedures – feedback from the discussion meeting .... 14
5.4. Final Advice Letters for procedures finalised the previous month ............ 14
6. **Pre-Authorisation Activities** 14

6.1. Paediatric investigation plans ................................................................. 14

6.2. ITF briefing meetings in the field of ATMPs ............................................. 14

6.3. Priority Medicines (PRIME) – Eligibility requests ................................ 14

   6.3.1. Month 0 - Start of the procedure ....................................................... 14

   6.3.2. Month 1 - Discussion of eligibility ...................................................... 14

   6.3.3. Month 2 – Recommendation of eligibility ........................................... 14

   6.3.4. Ongoing support .................................................................................. 14

7. **Organisational, regulatory and methodological matters** 15

7.1. Mandate and organisation of the CAT ...................................................... 15

    7.1.1. CAT membership .............................................................................. 15

    7.1.2. Vote by proxy .................................................................................... 15

    7.1.3. Election of CAT Vice-chairperson ..................................................... 15

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, Madrid (Spain) ................................................................. 15

7.1.5. CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden) ......................................................... 15

7.2. Coordination with EMA Scientific Committees ....................................... 15

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups .... 15

7.4. Cooperation with the EU regulatory network .......................................... 15

7.5. Cooperation with international regulators ............................................ 16

    7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan) .......................................................... 16

7.6. CAT work plan ....................................................................................... 16

    7.6.1. Report on experience with RWE studies to support EMA scientific committees .......................................................... 16

    7.6.2. European Rare Disease Registries: a collaborative effort to assess the quality and suitability of registries to describe the natural history of disease and treatment landscape of spinal muscular atrophy .......................................................... 16

7.6.3. Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials ................................................................. 16

7.7. Planning and reporting ........................................................................ 16

    7.7.1. Business Pipeline Report – 3 year Forecast report ................................. 16

7.8. Others .................................................................................................. 17


8. **Any other business** 17

8.1. Accessibility of PRIME reports in IRIS .................................................. 17

9. **Explanatory notes** 18
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 14-15 June 2023. See June 2023 CAT minutes (to be published post July 2023 CAT meeting).

1.2. **Adoption of agenda**

CAT agenda for 14-15 June 2023 meeting

1.3. **Adoption of the minutes**

CAT minutes for 15-18 May 2023 meeting

2. **Evaluation of ATMPs**

2.1. **Opinions**

No items

2.2. **Oral explanations**

No items

2.3. **Day 180 list of outstanding issues**

No items

2.4. **Day 120 list of questions**

No items

2.5. **Day 80 assessment reports**

No items

2.6. **Update on ongoing initial applications**

No items
2.7. **New applications**

2.7.1. **fidanacogene elaparvovec - PRIME - Orphan - EMEA/H/C/004774**

Pfizer Europe MA EEIG; Indicated for the treatment of severe and moderately severe haemophilia B

Scope: Timetable for assessment

**Action:** for adoption

2.8. **Withdrawal of initial marketing authorisation application**

No items

2.9. **Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**

No items

2.10. **Companion diagnostics**

2.10.1. **Initial consultation**

No items

2.10.2. **Follow-up consultation**

No items

2.11. **Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

2.11.1. **Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0031**

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken, Co-Rapporteur: Heli Suila, PRAC Rapporteur: Ulla Wändel Liminga

Scope: Clinical

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel
versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.

**Action:** for adoption

### 2.11.2. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0032/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken

Scope: Quality

**Action:** for adoption

Request for supplementary information adopted on 17.05.2023.

### 2.11.3. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0034

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeken

Scope: Quality, Request for supplementary information

**Action:** for adoption

### 2.11.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0013/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

**Action:** for adoption

Request for supplementary information adopted on 17.02.2023.

### 2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

**Action:** for adoption
<table>
<thead>
<tr>
<th>2.11.6.</th>
<th>Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bristol-Myers Squibb Pharma EEIG</td>
</tr>
<tr>
<td></td>
<td>Rapporteur: Concetta Quintarelli</td>
</tr>
<tr>
<td></td>
<td>Scope: Quality</td>
</tr>
<tr>
<td><strong>Action:</strong></td>
<td>for adoption</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.11.7.</th>
<th>CARVYKTI - ciltaacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Janssen-Cilag International NV</td>
</tr>
<tr>
<td></td>
<td>Rapporteur: Jan Mueller-Berghaus</td>
</tr>
<tr>
<td></td>
<td>Scope: Quality</td>
</tr>
<tr>
<td><strong>Action:</strong></td>
<td>for adoption</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.11.8.</th>
<th>Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0062/G</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amgen Europe B.V.</td>
</tr>
<tr>
<td></td>
<td>Rapporteur: Maija Tarkkanen</td>
</tr>
<tr>
<td></td>
<td>Scope: Quality, opinion</td>
</tr>
<tr>
<td><strong>Action:</strong></td>
<td>for adoption</td>
</tr>
</tbody>
</table>

Request for supplementary information adopted on 17.05.2023.

<table>
<thead>
<tr>
<th>2.11.9.</th>
<th>Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0069</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Novartis Europharm Limited</td>
</tr>
<tr>
<td></td>
<td>Rapporteur: Rune Kjeken</td>
</tr>
<tr>
<td></td>
<td>Scope: Quality</td>
</tr>
<tr>
<td><strong>Action:</strong></td>
<td>for adoption</td>
</tr>
</tbody>
</table>

Request for supplementary information adopted on 17.05.2023.
2.11.11. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0015

Orchard Therapeutics (Netherlands) B.V.
Rapporteur: Carla Herberts
Scope: Quality, request for supplementary information
Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/013

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus
Scope: Quality
Action: for adoption

2.13.2. Hemgenix - etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/REC/005

CSL Behring GmbH
Rapporteur: Silke Dorner
Scope: Quality, fulfilled
Action: for adoption

2.13.3. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/002.1

BioMarin International Limited
Rapporteur: Violaine Closson Carella
Scope: Clinical
MAH response to ANX 002 [Study protocol 270-601 as adopted in January 2023]:
To fulfil the request of PAM, the MAH opted for a prospective longitudinal study that is observational. Most of the concerns raised in this report are related to the observational nature of the study with regard to the examinations and tests required to achieve the objectives of the study.
Action: for adoption
2.13.4. **ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/004.1**

BioMarin International Limited  
Rapporteur: Violaine Closson Carella  
Scope: Clinical  
MAH response to ANX 004 [Study protocol Study 270-801] as adopted in January 2023:

This study is being undertaken to better characterise the long-term safety and effectiveness of Roctavian in patients in a real-world setting using periodic data extractions from registries databases to further substantiate the risk-benefit of Roctavian and to provide information on the long-term impact of treatment with Roctavian for approximately 15 years (risk of malignancy on the safety side and uncertainties on the durability on the efficacy side). This protocol is not the final version as the MAH plans to develop registry specific protocol to be added as appendices 2, 3, and 4 of the study protocol.

**Action:** for adoption

2.13.5. **ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/MEA/005**

BioMarin International Limited  
Rapporteur: Violaine Closson Carella  
Scope: Pharmacovigilance  
Survey of haematologists to assess the effectiveness of the additional risk minimisation measures (aRMMs) for Roctavian (valoctocogene roxaparvovec) (Version 1.0).

**Action:** for adoption

2.13.6. **Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/ANX/004.4**

Orchard Therapeutics (Netherlands) B.V.  
Rapporteur: Sol Ruiz  
Scope: Clinical and Pharmacovigilance  
Third interim patient registry / STRIM-0003. Title: Adenosine deaminase severe combined immunodeficiency (ADA-SCID) registry for patients treated with Strimvelis™ (or GSK2696273) gene therapy: long-term prospective, non-interventional follow-up of safety and effectiveness. [Interim reports submitted every 2 years.]

**Action:** for adoption

2.13.7. **Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/REC/009**

PTC Therapeutics International Limited  
Rapporteur: Maura O'Donovan
2.14. **GMP and GCP inspections requests**

No items

3. **Certification of ATMPs**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. **Opinion**

3.2. **Day 60 Evaluation Reports**

No items

3.3. **New Applications**

No items

4. **Scientific Recommendation on Classification of ATMPs**

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. **Neonatal human dermal fibroblast (nHDF) cell-produced living extracellular vascular tissue**

For regeneration, repair, or replacement of damaged blood vessels in patients with end-stage renal disease (ESRD), needing arterial bypass and with vascular trauma

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

4.1.2. **Bovine collagen membrane seeded with allogeneic mesenchymal stem cells derived from adipose tissue (ADSC)**

Treatment of patients who are undergoing a surgical procedure of coronary artery bypass grafting and have ischemic left ventricular dysfunction

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption
### 4.1.3. Lymphocytic Choriomeningitis Virus (LCMV) reassortant strain exerting efficient anti-tumoral activity

- **Treatment of metastatic solid cancers**
- **Scope:** Appointment of CAT Coordinator and adoption of timetable
- **Action:** for adoption

### 4.1.4. Human Cardiomyocytes (CM), Human Stromal Cells (StC)

- **Treatment of heart failure**
- **Scope:** Appointment of CAT Coordinator and adoption of timetable
- **Action:** for adoption

### 4.1.5. Doruxapapogenum ralaplasmidum (pGX3024), DNA plasmid encoding E6 and E7 proteins of HPV6 and HPV11

- **Treatment of recurrent respiratory papillomatosis**
- **Scope:** Appointment of CAT Coordinator and adoption of timetable
- **Action:** for adoption

### 4.1.6. TERT Ribonucleoprotein

- **Treatment of cancer**
- **Scope:** Appointment of CAT Coordinator and adoption of timetable
- **Action:** for adoption

### 4.2. Day 30 ATMP scientific recommendation

No items

### 4.3. Day 60 revised scientific recommendation (following list of questions)

No items

### 4.4. Finalisation of procedure

#### 4.4.1. Living human adult allogeneic immunomodulatory progenitor (IMP) cells

- **Treatment of myocardial scarring**
- **Scope:** European Commission raised no comments. ATMP scientific recommendation
- **Action:** for adoption
4.4.2. **Allogeneic viable natural killer (NK) cells CD56+ CD3-**

Treatment of patients with acute myeloid leukaemia (AML) who are in morphologic complete remission and for whom allogeneic haematopoietic stem cell transplantation (allo-HSCT) is not a suitable or preferred option

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.3. **Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene**

Treatment of Danon disease

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.5. **Follow-up and guidance**

No items

5. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. **New requests - appointment of CAT Rapporteurs**

5.1.1. **Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers**

**Timetable:**

- Start of procedure at SAWP: 05–08.06.2023
- Appointment of CAT Peer Reviewers: 14-16.06.2023
- SAWP first reports: 26.06.2023
- CAT Peer Reviewer comments (NC/C): 30.06.2023
- CAT Peer Reviewer comments (Q): 05.07.2023
- Discussion at SAWP: 03-06.07.2023
- Discussion at CAT and feedback to SAWP: 12-14.07.2023

5.1.2. **Scientific advice procedures starting at the next SAWP meeting**

**Timetable:**

- Start of procedure at SAWP: 03-06.07.2023
- Appointment of CAT Peer Reviewers: 12-14.07.2023
- SAWP first reports: 21.08.2023
- CAT Peer Reviewer comments (NC/C): 25.08.2023
- CAT Peer Reviewer comments (Q): 30.08.2023
- Discussion at SAWP: 28-31.08.2023
- Discussion at CAT and feedback to SAWP: 06-08.09.2023
5.2. Procedures discussed at SAWP – 1st reports, D40 JRIs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

<table>
<thead>
<tr>
<th>Timetable for assessment:</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure start:</td>
<td>31/05/2023</td>
</tr>
<tr>
<td>EMA scientific officer draft report sent to SAWP reviewer:</td>
<td>16/06/2023</td>
</tr>
<tr>
<td>Report circulated to SAWP:</td>
<td>26/06/2023</td>
</tr>
<tr>
<td>SAWP recommendation:</td>
<td>06/07/2023</td>
</tr>
<tr>
<td>CAT recommendation (for ATMP):</td>
<td>14/07/2023</td>
</tr>
<tr>
<td>CHMP adoption of report and final recommendation:</td>
<td>20/07/2023</td>
</tr>
</tbody>
</table>

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items
7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

**Action:** for information

7.1.2. Vote by proxy

**Action:** for information

7.1.3. Election of CAT Vice-chairperson

**Action:** for information

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, Madrid (Spain)

CAT: Sol Ruiz, Marcos Timon  
Scope: Topics for discussion at the upcoming SRLM  
**Action:** for discussion

7.1.5. CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden)

CAT: Maria Lüttgen, Lisbeth Barkholt  
Scope: Presentations  
**Action:** for information

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items
7.5. **Cooperation with international regulators**

7.5.1. **ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)**

CAT: Ilona Reischl
Scope: Agenda of the teleconference that will take place on 22 June 2023
*Action*: for information

7.6. **CAT work plan**

7.6.1. **Report on experience with RWE studies to support EMA scientific committees**

Scope: Presentation on the main findings of the report on the experience with real world evidence (RWE) studies to support regulatory decision making
*Action*: for information

7.6.2. **European Rare Disease Registries: a collaborative effort to assess the quality and suitability of registries to describe the natural history of disease and treatment landscape of spinal muscular atrophy**

CAT: Kieran Breen, Mencia de Lemus, Lisbeth Barkholt
Scope: Acceptance of an abstract for the spinal muscular dystrophy (SMA) study at ICPE 2023; the objective of this study is the conduct of a fit-for-purpose (FFP) assessment of European SMA registries from the TREAT-NMD network and assess their suitability to participate in the first ever EMA-funded registry study in collaboration with CAT
*Action*: for information

7.6.3. **Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials**

CAT topic leads: Ilona Reischl, Rune Kjeken, Claire Beuneu, Alessandro Aiuti
Scope: Alignment of the quality, non-clinical and clinical parts of the guideline (concepts, terminology and abbreviations) for investigational ATMPs in clinical trials
*Action*: for discussion

7.7. **Planning and reporting**

7.7.1. **Business Pipeline Report – 3 year Forecast report**

Scope: Q2/2023 update of the business pipeline report for the human scientific committees
*Action*: for information
7.8. **Others**

7.8.1. **International Society for Gene and Cell therapy (ISCT) Paris 2023**

CAT: Ilona Reischl

Scope: Feedback from the ISCT Global Regulators feedback on the use of unproven cell and gene products (30.05.2023) and from the ISCT 2023 Annual Meeting (31.05.2023 - 03.06.2023)

**Action:** for information

8. **Any other business**

8.1. **Accessibility of PRIME reports in IRIS**

Scope: Update to the committee on the accessibility of PRIME reports in IRIS

**Action:** for information

Date of next CAT meeting:
12-14 July 2023
9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus
AR: Assessment Report
ATMP: Advanced Therapy Medicinal Product
BWP: Biologics Working Party
CAT: Committee for Advanced Therapies
CHMP: Committee for Medicinal Product for Human Use
COMP: Committee for Orphan Medicinal Products
CTFG: Clinical Trial Facilitation Group
DG: Drafting Group
EC: European Commission
EU NTC: European Union Network Training Centre
ERA: Environmental Risk Assessment
FDA: Food and Drug Administration
FL: Final Letter
GCG: Guideline Consistency Group
GCP: Good Clinical Practice
GLP: Good Laboratory Practice
GMO: Genetically-modified organism
GMP: Good Manufacturing Practice
GTMP: Gene Therapy Medicinal Product
HTA: Health Technology Assessment Bodies
HSPC: Hematopoietic Stem and Progenitor Cells
ITF: Innovative Task Force
JR: Joint Report
LoOI: List of outstanding issues
LoQ: List of questions
MA: Marketing Authorisation
MAA: Marketing Authorisation Application
MAH: Marketing Authorisation Holder
MNAT: Multinational assessment team
MSC: Mesenchymal stem cells
PDCO: Paediatric Committee
PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
PPIP: Paediatric Investigation Plan
PL: Package leaflet
PRAC: Pharmacovigilance and Risk Assessment Committee #
Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1 to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.4) or a List of outstanding issues or opinion (section 2.7 Ongoing evaluation procedures). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.
New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.
Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/